On January 29, Gelonghui (688238.SH) announced that according to preliminary estimates by the finance department, it is expected to achieve operating income of 20.00 million yuan to 224.40 million yuan in 2023, a decrease of 67.3043 million yuan to 89.3043 million yuan over the same period last year, a year-on-year decrease of 23% to 31%. The company expects to achieve net profit attributable to the owners of the parent company in 2023 compared with the same period last year, from -129.00 million yuan to -1130,000 yuan, a decrease of 15.20.052 million yuan to 168.0252 million yuan over the same period last year. The company expects to achieve net profit of -135.0 million yuan to -118.0 million yuan after deducting non-recurring profit and loss attributable to the owners of the parent company in 2023, a decrease of 148.7952 million yuan to 165.7952 million yuan over the same period last year.

As the external economic market environment continues to weaken and uncertainty increases, global and domestic biotechnology financing has slowed markedly. The financing progress of downstream customers in the gene cell therapy CDMO industry is generally weaker than expected, which has adversely affected the company's domestic CDMO business expansion, order size, and project delivery. Since the company's CDMO business accounts for a large share of revenue, its fluctuation led to a year-on-year decline in revenue during the reporting period.